News
06-18-2021, 12:57 AM
KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.
More... (https://www.news-medical.net/news/20210618/KIYATECe28099s-test-results-accurately-predict-treatment-response-in-recurrent-high-grade-glioma-patients.aspx)
More... (https://www.news-medical.net/news/20210618/KIYATECe28099s-test-results-accurately-predict-treatment-response-in-recurrent-high-grade-glioma-patients.aspx)